ARCA biopharma Inc (ABIO)

2.40
0.06 2.80
NASDAQ : Health Care
Prev Close 2.34
Open 2.30
Day Low/High 2.25 / 2.40
52 Wk Low/High 2.73 / 8.40
Volume 28.92K
Avg Volume 20.40K
Exchange NASDAQ
Shares Outstanding 9.08M
Market Cap 21.07M
EPS -1.80
P/E Ratio 1.16
Div & Yield N.A. (N.A)

Latest News

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc.

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to the development of genetically-targeted therapies for cardiovascular diseases, today announced the randomization of...

ARCA Biopharma To Present At The Dawson James Securities Second Annual Growth Stock Conference

ARCA Biopharma To Present At The Dawson James Securities Second Annual Growth Stock Conference

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a...

ARCA Biopharma Named Winner Of Corporate LiveWire Healthcare And Lifesciences Innovation Award

ARCA Biopharma Named Winner Of Corporate LiveWire Healthcare And Lifesciences Innovation Award

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that is has been named as one...

ARCA Biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial

ARCA Biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 100 th patient has...

ARCA Biopharma Announces Second Quarter 2016 Financial Results And Provides Business Update

ARCA Biopharma Announces Second Quarter 2016 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2016, and provided a...

ARCA Biopharma Announces First Quarter 2016 Financial Results And Provides Business Update

ARCA Biopharma Announces First Quarter 2016 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a...

ARCA Biopharma Announces 75th Patient Enrolled In GENETIC-AF Phase 2B/3 Clinical Trial

ARCA Biopharma Announces 75th Patient Enrolled In GENETIC-AF Phase 2B/3 Clinical Trial

ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the 75 th patient has been enrolled in GENETIC-AF, a Phase 2B/3...

ARCA Biopharma Announces Fiscal Year 2015 Financial Results And Provides Business Update

ARCA Biopharma Announces Fiscal Year 2015 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2015, and provided a...

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc. (Photo: Business Wire)

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today provided an update on GENETIC-AF, the Company's Phase 2B/3 clinical trial...

ARCA Biopharma To Present At The 27th Annual Piper Jaffray Healthcare Conference

ARCA Biopharma To Present At The 27th Annual Piper Jaffray Healthcare Conference

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it will make a presentation at the 27 th Annual Piper Jaffray...

ARCA Biopharma Announces Third Quarter 2015 Financial Results And Provides Business Update

ARCA Biopharma Announces Third Quarter 2015 Financial Results And Provides Business Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2015, and provided...

ARCA Biopharma CEO Michael Bristow To Present In Two Sessions At The American Heart Association Scientific Sessions 2015

ARCA Biopharma CEO Michael Bristow To Present In Two Sessions At The American Heart Association Scientific Sessions 2015

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Michael R.

4 Stocks Under $10 Making Big Up Moves on Big Volume

4 Stocks Under $10 Making Big Up Moves on Big Volume

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Gencaro™ Potential Efficacy Preventing Atrial Flutter In Heart Failure Paper To Be Presented At 2015 HFSA Annual Scientific Meeting

Gencaro™ Potential Efficacy Preventing Atrial Flutter In Heart Failure Paper To Be Presented At 2015 HFSA Annual Scientific Meeting

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper "Bucindolol Prevents Atrial Flutter via the Beta-1 389...

ARCA Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference

ARCA Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its Chief Operating Officer, Thomas A.

ARCA Biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments

ARCA Biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2015, and provided an...

ARCA Biopharma Announces Closing Of $37 Million Private Placement

ARCA Biopharma Announces Closing Of $37 Million Private Placement

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the closing of the previously announced private placement financing...

ARCA Biopharma Announces $37 Million Private Placement

ARCA Biopharma Announces $37 Million Private Placement

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into a securities purchase agreement for a private...

ARCA biopharma (ABIO) Stock Surges Today on FDA Fast Track Designation

ARCA biopharma (ABIO) Stock Surges Today on FDA Fast Track Designation

Shares of ARCA biopharma (ABIO) soared Monday after the company announced that the Food and Drug Administration had designated as a Fast Track development program the investigation of Gencaro.

Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire)

Dr. Michael Bristow, CEO, ARCA Biopharma (Photo: Business Wire)

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the U.

ARCA Biopharma Provides GENETIC-AF Clinical Trial Update

ARCA Biopharma Provides GENETIC-AF Clinical Trial Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today provided an update on GENETIC-AF, the Company's Phase 2B/3 clinical trial...

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

ARCA Biopharma Announces Patent Issuance For Methods And Compositions Of S-isomer Formulation Of Gencaro

ARCA Biopharma Announces Patent Issuance For Methods And Compositions Of S-isomer Formulation Of Gencaro

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.

Arca Biopharma Announces Activation Of First Canadian Genetic-AF Clinical Trial Site

Arca Biopharma Announces Activation Of First Canadian Genetic-AF Clinical Trial Site

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the activation of the first GENETIC-AF clinical trial site in...

ARCA Biopharma Receives FDA Orphan Drug Designation For RNAPc2 As A Potential Treatment For Ebola

ARCA Biopharma Receives FDA Orphan Drug Designation For RNAPc2 As A Potential Treatment For Ebola

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the U.

ARCA Biopharma Announces Management Transitions

ARCA Biopharma Announces Management Transitions

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced three management team transitions.

LabCorp/ARCA Biopharma GENETIC-AF Poster Presented At The 18th Annual Scientific Meeting Of The Heart Failure Society Of America

LabCorp/ARCA Biopharma GENETIC-AF Poster Presented At The 18th Annual Scientific Meeting Of The Heart Failure Society Of America

ARCA biopharma, Inc. (ARCA) (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America ® ...